Reviews:
Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy
Metrics: PDF 2520 views | HTML 6352 views | ?
Abstract
Qian Gou1,2,*, Xin Gong2,*, Jianhua Jin1,*, Juanjuan Shi2 and Yongzhong Hou1,2
1Department of Oncology, Affiliated Wujin People’s Hospital, Jiangsu University, Changzhou, 212017, PR China
2Institute of Life Sciences, Jiangsu University, Zhenjiang, 212013, PR China
*These authors contributed equally to this work
Correspondence to:
Yongzhong Hou, email: [email protected]
Keywords: PPARs, ligands, cancer therapy, cell signaling
Received: March 04, 2017 Accepted: July 18, 2017 Published: July 27, 2017
ABSTRACT
Peroxisome-proliferator-activated receptors (PPARs) are nuclear hormone receptors including PPARα, PPARδ and PPARγ, which play an important role in regulating cancer cell proliferation, survival, apoptosis, and tumor growth. Activation of PPARs by endogenous or synthetic compounds regulates tumor progression in various tissues. Although each PPAR isotype suppresses or promotes tumor development depending on the specific tissues or ligands, the mechanism is still unclear. In this review, we summarized the regulative mechanism of PPARs on cancer progression.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19610